The US FDA has scheduled a meeting of the Pediatric Advisory Committee (PEDAC) for Wednesday, April 29, 2020. The Committee will discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA). The Agency’s announcement did not list the specific products that will be discussed.

Update as of March 20, 2020: This meeting has been cancelled. The FDA, like other government agencies, is taking the necessary steps to ensure the agency is prepared to continue our vital public health mission in the event that our day-to-day operations are impacted by the COVID-19 public health emergency. Therefore, we are canceling or postponing all non-essential meetings through the month of April. We will reassess on an ongoing basis for future months. Where possible the agency will leverage technology to host meetings allowing for remote participation.